ES2216055T3 - Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob. - Google Patents

Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob.

Info

Publication number
ES2216055T3
ES2216055T3 ES96926873T ES96926873T ES2216055T3 ES 2216055 T3 ES2216055 T3 ES 2216055T3 ES 96926873 T ES96926873 T ES 96926873T ES 96926873 T ES96926873 T ES 96926873T ES 2216055 T3 ES2216055 T3 ES 2216055T3
Authority
ES
Spain
Prior art keywords
methods
lipids
blood
reduce
reduced levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96926873T
Other languages
English (en)
Inventor
Mary Ann Pelleymounter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2216055T3 publication Critical patent/ES2216055T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

SE PROPORCIONAN METODOS Y COMPOSICIONES RELACIONADAS CON EL USO DE LAS PROTEINAS OB PARA EL TRATAMIENTO DE ESTADOS RELACIONADOS CON LOS NIVELES DE LIPIDOS SANGUINEOS. ESTOS METODOS Y COMPOSICIONES INCLUYEN LOS QUE SON UTILES PARA EL TRATAMIENTO DE COLESTEROL ELEVADO, NIVELES DE TRIGLICERIDOS ELEVADOS, PLACA ARTERIAL, HIPERTENSION, Y PREVENCION DE FORMACION DE PIEDRAS DE LA VESICULA BILIAR.
ES96926873T 1995-08-17 1996-08-02 Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob. Expired - Lifetime ES2216055T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51626395A 1995-08-17 1995-08-17

Publications (1)

Publication Number Publication Date
ES2216055T3 true ES2216055T3 (es) 2004-10-16

Family

ID=24054813

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96926873T Expired - Lifetime ES2216055T3 (es) 1995-08-17 1996-08-02 Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob.

Country Status (13)

Country Link
US (1) US20020147142A1 (es)
EP (1) EP0865294B1 (es)
JP (1) JP4173913B2 (es)
AT (1) ATE259650T1 (es)
AU (1) AU6688896A (es)
CA (1) CA2229450A1 (es)
DE (1) DE69631605T2 (es)
DK (1) DK0865294T3 (es)
ES (1) ES2216055T3 (es)
MX (1) MX9801159A (es)
PT (1) PT865294E (es)
WO (1) WO1997006816A1 (es)
ZA (1) ZA966798B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
JPH11508134A (ja) * 1995-06-22 1999-07-21 イーライ・リリー・アンド・カンパニー 肥満症蛋白質中間体およびその製法と使用
US5830450A (en) * 1996-06-19 1998-11-03 Lallone; Roger L. Compositions of leptin bound to an apolipoprotein
US7332338B2 (en) 1996-10-04 2008-02-19 Lexicon Pharmaceuticals, Inc. Vectors for making genomic modifications
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6436707B1 (en) 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6808921B1 (en) 1998-03-27 2004-10-26 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
ATE280588T1 (de) * 1998-08-10 2004-11-15 Amgen Inc Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
WO2001021647A2 (en) * 1999-09-22 2001-03-29 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
WO2003034996A2 (en) 2001-10-22 2003-05-01 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
GB0307367D0 (en) * 2003-03-29 2003-05-07 Twg Composition and method for treating the gastro-intestinal tract
EP1462116A1 (en) * 2003-03-29 2004-09-29 Villitech SARL Composition for treating the gastrointestinal tract
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP1814590B2 (en) 2004-11-01 2013-12-11 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US7629315B2 (en) * 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
WO2012050925A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Highly soluble leptins
RS58010B1 (sr) 2012-09-27 2019-02-28 Childrens Medical Ct Corp Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
AU2014354831B2 (en) 2013-11-26 2017-10-26 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CA3036551A1 (en) 2016-09-12 2018-03-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
PT865294E (pt) 2004-07-30
US20020147142A1 (en) 2002-10-10
AU6688896A (en) 1997-03-12
EP0865294A1 (en) 1998-09-23
JPH11511165A (ja) 1999-09-28
DK0865294T3 (da) 2004-06-28
EP0865294B1 (en) 2004-02-18
MX9801159A (es) 1998-05-31
CA2229450A1 (en) 1997-02-27
ATE259650T1 (de) 2004-03-15
WO1997006816A1 (en) 1997-02-27
ZA966798B (en) 1997-02-19
DE69631605D1 (de) 2004-03-25
DE69631605T2 (de) 2005-01-05
JP4173913B2 (ja) 2008-10-29

Similar Documents

Publication Publication Date Title
ES2216055T3 (es) Metodos para reducir o mantener niveles reducidos de lipidos en sangre usando composiciones de proteina ob.
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
ATE238038T1 (de) Liposomale formulierungen von mitoxantron
CY1112927T1 (el) Αντισωματα κατα της ανθρωπινης il-12
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
DK1329458T3 (da) Peptider som sænker blodglucoseniveauer
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
ATE116848T1 (de) Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris.
DE69806801T2 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
DE69822496D1 (de) Lipidkomplex-lyophilisat von wasserunlöslichen porphyrinen
DK0858504T3 (da) Diagnostiske midler mod og behandlinger af periodontale sygdomme
DE69405919T2 (de) Zusammensetzungen zur Behandlung von Keratinfasern
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
ATE211650T1 (de) Verwendung von topische präparationen mit glyceryl trinitrat und lanolin zur behandlung von erektilen funktionsstörungen
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
NO992531L (no) Fremgangsmåter ved fremstilling av rekombinant protein
EA199800953A1 (ru) Компонент в, используемый в качестве рубцующего агента, содержащая его фармацевтическая композиция и способ лечения
ITMI940414A0 (it) Procedimento per la coniugazione di proteine di interesse terapeutico o diagnostico
UA9703A (uk) Антипротеіназний засіб
DE9321428U1 (de) Konservierte Polysiloxanemulsionen zur Behandlung von Tissues